Inventor · disambiguated record
Nicholas J. Papadopoulos
Also filed as: PAPADOPOULOS NICHOLAS · PAPADOPOULOS NICHOLAS J
93 granted patents·31 pending applications·4,550 citations·filing 1999–2024
99Inventor score
Top patents by PatentIndex Score
124 records- 0199US10392430B2Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2017·Granted Aug 27, 2019·37 cites·2 claims
- 0299US9708386B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2015·Granted Jul 18, 2017·41 cites·5 claims
- 0399US9657102B2Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereofREGENERON PHARMA·Filed 2013·Granted May 23, 2017·125 cites·12 claims
- 0499US8735095B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2012·Granted May 27, 2014·103 cites·29 claims
- 0599US8343737B2Cell culture compositions capable of producing a VEGF-binding fusion polypeptideREGENERON PHARMA·Filed 2011·Granted Jan 1, 2013·73 cites·12 claims
- 0699US8043617B2Human antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2009·Granted Oct 25, 2011·91 cites·9 claims
- 0799US8029791B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2008·Granted Oct 4, 2011·73 cites·9 claims
- 0899US7704500B2Methods of inhibiting ascites formation with modified chimeric VEGF polypeptidesREGENERON PHARMA·Filed 2008·Granted Apr 27, 2010·59 cites·8 claims
- 0999US7608693B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2008·Granted Oct 27, 2009·158 cites·10 claims
- 1099US7582298B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2007·Granted Sep 1, 2009·390 cites·7 claims
- 1199US7396664B2VEGF-binding fusion proteins and nucleic acids encoding the sameREGENERON PHARMA·Filed 2005·Granted Jul 8, 2008·171 cites·11 claims
- 1299US7374757B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2004·Granted May 20, 2008·137 cites·7 claims
- 1399US7374758B2Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereofREGENERON PHARMA·Filed 2004·Granted May 20, 2008·124 cites·3 claims
- 1499US7306799B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 11, 2007·140 cites·11 claims
- 1599US7303747B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 4, 2007·112 cites·6 claims
- 1699US7087411B2Fusion protein capable of binding VEGFREGENERON PHARMA·Filed 2003·Granted Aug 8, 2006·345 cites·16 claims
- 1799US7070959B1Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2000·Granted Jul 4, 2006·196 cites·15 claims
- 1898US9987500B2Human antibodies to PD-1REGENERON PHARMA·Filed 2015·Granted Jun 5, 2018·126 cites·10 claims
- 1998US9938345B2Human antibodies to PD-L1REGENERON PHARMA·Filed 2015·Granted Apr 10, 2018·37 cites·8 claims
- 2098US9637535B2IL-33 antagonists and uses thereofREGENERON PHARMA·Filed 2014·Granted May 2, 2017·36 cites·33 claims
- 2198US9540449B2Anti-PCSK9 antibodies with pH-dependent binding characteristicsREGENERON PHARMA·Filed 2013·Granted Jan 10, 2017·57 cites·13 claims
- 2298US9453072B2Anti-IL-33 antibodiesREGENERON PHARMA·Filed 2014·Granted Sep 27, 2016·49 cites·20 claims
- 2398US9302015B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Apr 5, 2016·82 cites·57 claims
- 2498US9139644B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2013·Granted Sep 22, 2015·44 cites·7 claims
- 2598US9132192B2Anti-EGFR antibodies and uses thereofREGENERON PHARMA·Filed 2013·Granted Sep 15, 2015·72 cites·4 claims
- 2698US8647842B2Methods for producing a fusion protein capable of binding VEGFPAPADOPOULOS NICHOLAS J·Filed 2012·Granted Feb 11, 2014·79 cites·14 claims
- 2798US7972598B2VEGF-binding fusion proteins and therapeutic uses thereofREGENERON PHARMA·Filed 2009·Granted Jul 5, 2011·76 cites·1 claims
- 2898US7964377B2Nucleic acid molecule encoding a fusion polypeptide capable of binding VEGFREGENERON PHARMA·Filed 2008·Granted Jun 21, 2011·45 cites·8 claims
- 2998US7635474B2VEGF-binding fusion proteinsREGENERON PHARMA·Filed 2008·Granted Dec 22, 2009·77 cites·4 claims
- 3098US7524499B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2008·Granted Apr 28, 2009·52 cites·3 claims
- 3198US7521049B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2007·Granted Apr 21, 2009·74 cites·15 claims
- 3298US7399612B2VEGF-binding fusion proteins and nucleic acids encoding the sameREGENERON PHARMA·Filed 2006·Granted Jul 15, 2008·58 cites·7 claims
- 3398US7303746B2Methods of treating eye disorders with modified chimeric polypeptidesREGENERON PHARMA·Filed 2004·Granted Dec 4, 2007·117 cites·5 claims
- 3498US7279159B2VEGF inhibitor polypeptidesREGENERON PHARMA·Filed 2004·Granted Oct 9, 2007·191 cites·8 claims
- 3597US8337839B2High affinity human antibodies to human IL-4 receptorMARTIN JOEL H·Filed 2011·Granted Dec 25, 2012·39 cites·5 claims
- 3697US8084234B2Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGFPAPADOPOULOS NICHOLAS J·Filed 2010·Granted Dec 27, 2011·54 cites·13 claims
- 3797US8075887B2High affinity human antibodies to human IL-4 receptorMARTIN JOEL H·Filed 2009·Granted Dec 13, 2011·42 cites·5 claims
- 3897US7605237B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2007·Granted Oct 20, 2009·194 cites·6 claims
- 3997US7534868B1Human antibodies to human delta like ligand 4REGENERON PHARMA·Filed 2009·Granted May 19, 2009·38 cites·6 claims
- 4097US7488806B2Human antibodies to human delta like ligand 4REGENERON PHARMA·Filed 2008·Granted Feb 10, 2009·41 cites·8 claims
- 4196US9884916B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2016·Granted Feb 6, 2018·13 cites·7 claims
- 4295US10011647B2IL-33 antagonists and uses thereofREGENERON PHARMA·Filed 2017·Granted Jul 3, 2018·8 cites·36 claims
- 4395US10000564B2Methods of treating an inflammatory condition or sensitivity to an allergen with anti-IL-33 antibodiesREGENERON PHARMA·Filed 2016·Granted Jun 19, 2018·14 cites·38 claims
- 4495US8597898B2Fusion polypeptides capable of activating receptorsREGENERON PHARMA·Filed 2012·Granted Dec 3, 2013·16 cites·22 claims
- 4595US7919593B2Human antibodies to human delta like ligand 4REGENERON PHARMA·Filed 2007·Granted Apr 5, 2011·25 cites·22 claims
- 4695US7534604B2Fusion polypeptides capable of activating receptorsREGENERON PHARMA·Filed 2005·Granted May 19, 2009·41 cites·9 claims
- 4794US11578135B2Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereofREGENERON PHARMA·Filed 2019·Granted Feb 14, 2023·8 cites·14 claims
- 4894US8927233B2Fusion polypeptides capable of activating receptorsREGENERON PHARMA·Filed 2013·Granted Jan 6, 2015·16 cites·34 claims
- 4994US8865430B2Fusion polypeptides capable of activating receptorsREGENERON PHARMA·Filed 2013·Granted Oct 21, 2014·16 cites·15 claims
- 5094US8338135B2High affinity human antibodies to human IL-4 receptorSTEVENS SEAN·Filed 2011·Granted Dec 25, 2012·33 cites·12 claims
Showing the top 50 of 124 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Nicholas J. Papadopoulos files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →